Stereotactic body radiotherapy for organ-confined prostate cancer

Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008, 358 (12): 1250-1261. 10.1056/NEJMoa074311.

Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC: Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000, 92 (19): 1582-1592. 10.1093/jnci/92.19.1582.

Robinson JW, Moritz S, Fung T: Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002, 54 (4): 1063-1068. 10.1016/S0360-3016(02)03030-4.

Siglin J, Kubicek GJ, Leiby B, Valicenti RK: Time of Decline in Sexual Function After External Beam Radiotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2010, 76 (1): 31-35.

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008, 149 (3): 185-191.

Dasu A: Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol (R Coll Radiol). 2007, 19 (5): 289-301.

Collins CD, Lloyd-Davies RW, Swan AV: Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol). 1991, 3 (3): 127-132.

Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J, Weerasinghe S, Abeysinghe P: Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006, 66 (4): 1072-1083.

Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W: Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005, 23 (25): 6132-6138. 10.1200/JCO.2005.06.153.

Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A: Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007, 68 (5): 1424-1430.

Livsey JE, Cowan RA, Wylie JP, Swindell R, Read G, Khoo VS, Logue JP: Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys. 2003, 57 (5): 1254-1259.

Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G: High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys. 2005, 61 (5): 1306-1316.

Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D, Vicini FA: Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol. 2003, 169 (3): 974-979. 10.1097/01.ju.0000052720.62999.a9. discussion 979-980

Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J: Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007, 67 (4): 1099-1105.

King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC: Stereotactic Body Radiotherapy for Localized Prostate Cancer: Interim Results of a Prospective Phase II Clinical Trial. Int J Radiat Oncol Biol Phys. 2009, 73 (4): 1043-1048.

Romanelli P, Schaal DW, Adler JR: Image-guided radiosurgical ablation of intra- and extra-cranial lesions. Technol Cancer Res Treat. 2006, 5 (4): 421-428.

Hara W, Patel D, Pawlicki T, Cotrutz C, Presti J, King C: Hypofractionated stereotactic radiotherapy for prostate cancer: early results. Int J Radiat Oncol Biol Phys. 2006, 66: S324-325.

Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG: Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000, 56 (6): 899-905. 10.1016/S0090-4295(00)00858-X.

National Institutes of Health: Common toxicity criteria. version 2.0 edn. 1998, National Institutes of Health

Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006, 65 (4): 965-974.

Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox JD: Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys. 2005, 62 (3): 706-713.

Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC: Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005, 61 (4): 1019-1034.

Beckendorf V, Guerif S, Le Prise E, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bachaud JM, Maingon P, Lagrange JL, Malissard L, Simon JM, Pommier P, Hay MH, Dubray B, Luporsi E, Bey P: The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys. 2004, 60 (4): 1056-1065.

Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A: Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008, 70 (1): 67-74.

Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. Jama. 2005, 294 (10): 1233-1239. 10.1001/jama.294.10.1233.

Simone NL, Menard C, Soule BP, Albert PS, Guion P, Smith S, Godette D, Crouse NS, Sciuto LC, Cooley-Zgela T, Camphausen K, Coleman CN, Singh AK: Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score. Int J Radiat Oncol Biol Phys. 2008, 70 (1): 90-95.

Athanassiou H, Antonadou D, Coliarakis N, Kouveli A, Synodinou M, Paraskevaidis M, Sarris G, Georgakopoulos GR, Panousaki K, Karageorgis P, Throuvalas N: Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys. 2003, 56 (4): 1154-1160. 10.1016/S0360-3016(03)00187-1.

Duchesne GM, Williams SG, Das R, Tai KH: Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results. Radiother Oncol. 2007, 84 (2): 128-134. 10.1016/j.radonc.2007.05.019.

King CR, Lo A, Kapp DS: Testicular dose from prostate cyberknife: a cautionary note. Int J Radiat Oncol Biol Phys. 2009, 73 (2): 636-637. author reply 637

Daniell HW, Clark JC, Pereira SE, Niazi ZA, Ferguson DW, Dunn SR, Figueroa ML, Stratte PT: Hypogonadism following prostate-bed radiation therapy for prostate carcinoma. Cancer. 2001, 91 (10): 1889-1895. 10.1002/1097-0142(20010515)91:10<1889::AID-CNCR1211>3.0.CO;2-U.

Bruheim K, Svartberg J, Carlsen E, Dueland S, Haug E, Skovlund E, Tveit KM, Guren MG: Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH. Int J Radiat Oncol Biol Phys. 2008, 70 (3): 722-727.

Yogeswaren ST, Teh BS, Mai W, Childress C, McGary JE, Grant WH, Butler E: Radiation dose to testicles and serum testosterone levels in low risk prostate cancer patients undergoing intensity-modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys. 2004, 60 (1): S456-10.1016/j.ijrobp.2004.07.364.